Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34,629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K. Paz-Ares L, et al. Among authors: shi y. Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611. Ann Oncol. 2017. PMID: 28426106 Free PMC article. Clinical Trial.
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F. Witzig TE, et al. Among authors: shi y. Ann Oncol. 2018 Mar 1;29(3):707-714. doi: 10.1093/annonc/mdx764. Ann Oncol. 2018. PMID: 29253068 Free article. Clinical Trial.
Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study.
Xing P, Zheng X, Wang Y, Chu T, Wang S, Jiang J, Qian J, Han X, Ding L, Wang Y, Cui L, Li H, Li L, Chen X, Han B, Hu P, Shi Y. Xing P, et al. Among authors: shi y. ESMO Open. 2022 Jun;7(3):100473. doi: 10.1016/j.esmoop.2022.100473. Epub 2022 May 6. ESMO Open. 2022. PMID: 35526510 Free PMC article.
Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428].
Shi Y, Wu L, Yu X, Xing P, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y. Shi Y, et al. Among authors: shi j. Ann Oncol. 2021 Apr;32(4):576. doi: 10.1016/j.annonc.2021.01.009. Ann Oncol. 2021. PMID: 33736838 Free article.
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC).
Shi Y, Wu L, Yu X, Xing P, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y. Shi Y, et al. Among authors: shi j. Ann Oncol. 2020 Dec;31 Suppl 7:S1428. doi: 10.1016/j.annonc.2020.10.517. Epub 2020 Dec 13. Ann Oncol. 2020. Retraction in: Ann Oncol. 2021 Apr;32(4):576. doi: 10.1016/j.annonc.2021.01.009 PMID: 33517977 Free article. Retracted.
34,629 results
You have reached the last available page of results. Please see the User Guide for more information.